Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | IM |
The patient received 2 doses (on day 0 and day 7) of RabAvert but was not aware of a third dose; Case reference number US-BN-2025-001521 is a spontaneous case initially received from a consumer via agency (reference number: USBAV25-2235 on 08-Sep-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 17-Jul-2025, the patient received the first dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown, expiration date: unknown) at an unknown dose, intramuscularly, at an unknown site of administration for pre-exposure due to work in veterinary clinic. On 24-Jul-2025, seven days after the first dose, the patient received the second dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown, expiration date: unknown) at an unknown dose, intramuscularly, at an unknown site of administration for pre-exposure. Patient did not get third dose of RabAvert. (explicitly coded as 'inappropriate schedule of product administration '). At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert. Additional information received from consumer via Med communication on 08-Sep-2025 included: new reference number (USBAV25-2240); Reporter's Comments: A female patient of unspecified age did not get the third dose of RabAvert for pre-exposure due to work in veterinary clinic, which as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect vaccine, but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age did not get the third dose of RabAvert for pre-exposure due to work in veterinary clinic, which as inappropriate schedule of product administration. It was unknown if the patient experienced any adverse event due to RabAvert. Inappropriate schedule of product administration is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. Causality is not related to suspect vaccine, but to human factor. The case is non-serious.
Comments: NONE